David Weber

David joined Ampersand as an Executive in Residence in 2020 and has served as an Executive Advisor since 2023. David currently sits on the Board of Directors at Ampersand portfolio company Leinco Technologies, a specialty manufacturer of early discovery research products including antibodies, recombinant proteins, ELISA kits, second step reagents and other life sciences products. David has over 50 years of experience in the life science tools sector with an emphasis on genomics, proteomics, cell biology, and bioprocessing. David’s main focus throughout his career has been commercialization strategy and execution. David is the founder and President of Weber & Associates, a life science consulting firm, and serves as a commercial advisor to a number of life science tools firms. David also serves as a Board member for SAMPS, a non-profit organization for life science sales and marketing professionals. Previously, he served as the first Chief Commercial Officer for Maravai LifeSciences. David also served in the same role for Affymetrix and drove a successful transformation of its commercial efforts until it was acquired by Thermo Fisher Scientific. Prior to Affymetrix, David held senior leadership roles at Amersham Biosciences, Eksigent Technologies, and Stratagene. David holds a B.S. in Biochemistry from Rutgers University and was named a Henry Rutgers Scholar and a member of Phi Beta Kappa